Jeff Evanson - 20 Jan 2023 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role: Chief Commercial Officer
Signature: /s/ Lawrence Kenyon, Attorney-in-Fact
Issuer symbol: OTLK
Transactions as of: 20 Jan 2023
Net transactions value: -$296,370
Form type: 4
Filing time: 24 Jan 2023, 19:08:49 UTC
Previous filing: 19 Jan 2023
Next filing: 19 Apr 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OTLK	Common Stock	Sale	$296,370	-267,000	-26%	$1.11	745,975	20 Jan 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were sold to cover taxes upon lapse of Issuer's repurchase right as to 75% of the shares as provided in that certain Consulting Agreement dated January 27, 2020.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.10 - $1.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Content

These shares were sold to cover taxes upon lapse of Issuer's repurchase right as to 75% of the shares as provided in that certain Consulting Agreement dated January 27, 2020.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.10 - $1.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.